Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study

Friis-Møller, Nina; Ledergerber, Bruno; Antúnes, Francisco; Blaxhult, Anders; Clumeck, Nathan; Gatell, JM; Johnson, AM; Loveday, Clive; An, Peng; Reiss, Peter; Vella, Stefano; Vetter, N; Hermans, Philippe; Sommereijns, Bernadette; Colebunders, Robert; Machala, Ladislav; Rozsypal, Hanuš; Nielsen, Jens; Lundgren, Jens D.; Benfield, T; Kirk, Ole; Gerstoft, Jan; Katzenstein, Terese L.; Røge, Birgit Thorup; Skinhøj, Peter; Pedersen, Court; Katlama, Christine; Riviere, Cynthia; Viard, JP; Saint-Marc, T; Vanhems, Philippe; Pradier, Christian; Dietrich, M.; Manegold, Christoph; Lunzen, Jan van; Miller, Veronica; Staszewski, Schlomo; Fd, Goebel; Salzberger, Bernd; Rockstroh, Jürgen K.; Kosmidis, J.; Gargalianos, Panagiotis; Sambatakou, Helen; Perdios, J.; Panos, George; Karydis, Ioannis; Filandras, A.; Bánhegyi, Dénes; Mulcahy, Fiona; Yust, Israel; Turner, Dan; Pollack, Shimon; Ben‐Ishai, Z.; Bentwich, Zvi; Maayan, Shlomo; Chiesi, Antonio; Arici, Claudio; Pristerà, Raffaele; Mazzotta, Francesco; Gabbuti, Andrea; Esposito, Roberto; Bedini, Andrea; Chirianni, Antonio; Montesarchio, E.; Vullo, Vincenzo; Santopadre, Paola; Narciso, Pasquale; Antinori, Andrea; Franci, Paolo; Zaccarelli, Mauro; Lazzarin, Adriano; Finazzi, Renato; Monforte, A d’Arminio; Hemmer, R; Staub, Thérèse; Bruun, JN; Mæland, A; Ormaasen, Vidar; Knysz, Brygida; Gąsiorowski, Jacek; Horban, Andrzéj; Prokopowicz, D; Wiercińska–Drapało, Alicja; Boroń-Kaczmarska, Anna; Pynka, M; Beniowski, Marek; H, Trocha; Kamal, Mehnaz; Proença, Rui; González-Lahoz, Juan; Díaz, Beatriz; García-Benayas, Teresa; Martín‐Carbonero, Luz; Soriano, Vicente; Clotet, Bonaventura; Jou, Antoni; Conejero, J. Alberto; Tural, Cristina; Miró, JM; Heidemann, B.; Pehrson, P; Weber, Rainer; Francioli, P.; Telenti, Amalio; Hirschel, Bernard; Soravia-Dunand, V.; Barton, Simon; Mercey, D; Ma, Jun; Mocroft, Amanda; Pinching, Anthony J.; Parkin, Jacqueline; Weber, Jonathan; Scullard, George; Fisher, Martin; Brettle, R P; Gjørup, Ida; Friis-Moeller, N; Cozzi‐Lepri, Alessandro; Mollerup, D.; Nielsen, Mette Juul; Hansen, Ann‐Brit Eg; Kristensen, Daniel; Aabolt, S; Cimposeu, P; Hansen, Lawrence A.; Kjær, Jesper

doi:10.1177/135965350200700103

Cited by 36 publications

(1 citation statement)

References 34 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In high income countries, a minority of HIV patients harbour multi-class drug resistance (MDR) viruses that have reduced susceptibility to almost all drugs, which makes it difficult to optimize therapy to halt viral replication in these patients [7,8]. HIV-MDR infection has been associated with a higher risk of clinical progression and death [9].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database

Lombardi

Giacomelli

Armenia

et al. 2021

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database

Lombardi

Giacomelli

Armenia

et al. 2021

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

Lampe

Gatell²,

Staszewski³

et al. 2006

Arch Intern Med

View full text Add to dashboard Cite

Background: Triple-combination antiretroviral therapy (CART) for human immunodeficiency virus infection has been in use for almost a decade, but the extent to which treatment success has changed is uncertain. We examined risk of initial virological failure of CART according to the year of starting therapy. Methods: We included subjects from 5 complete clinic cohorts in Europe and Canada who started CART without pre-viousantiretroviraltherapyfrom1996to2002with1ormore pre-CARTviralload(VL)measurementandCD4count.Based on the first VL measurement from 6 to 12 months after CART initiation, virological failure was defined as a VL of more than 500 copies/mL. We used the following 3 inclusion strategies: (1) including all subjects, with missing VL measurement counted as virological failure (n=3825; strategy A); (2) including all subjects with VL measurement (n=3120; strategy B); and (3) including all subjects receiving antiretroviral therapy at VL measurement (n=2890; strategy C). Results: From 1996 to 2002, risk of virological failure fell from 38.9% to 24.8% for strategy A, 28.4% to 12.0% for strategy B, and 22.8% to 8.2% for strategy C. Estimated relative reductions in risk (95% confidence interval) over the 7-year period, adjusted for cohort, demographic factors, pre-CART VL and CD4 count, and previous AIDS, were 48% (39%-56%), 64% (53%-73%), and 79% (69%-85%) for strategies A, B, and C, respectively. Reductions in risk were greatest from 1996 to 1999, with weaker trends subsequently. Trends remained but were attenuated after further adjustment for the starting regimen. Conclusions: Over a 7-year period of CART use in clinical practice, risk of initial virological failure of treatment has halved at least. These data suggest the trend is due to improvements in CART regimens and greater effectiveness of their use.

show abstract

Changing incidence of central nervous system diseases in the EuroSIDA cohort

Monforte

Cinque

Mocroft

et al. 2004

Annals of Neurology

242

View full text Add to dashboard Cite

A drastic decrease in incidence has been observed for most human immunodeficiency virus (HIV)-related opportunistic manifestations after use of highly active antiretroviral therapy (HAART). We assessed the trend of incidence of central nervous system (CNS) diseases in a prospective multicenter observational study involving 9,803 patients across Europe in the period 1994 to 2002 and analyzed patient and treatment variables associated with these conditions. Overall, 568 patients (5.8%) received a diagnosis of a new CNS disease. Incidence decreased significantly from 5.9 per 100 person-year in 1994 to 0.5 in 2002. Overall, the decrease was 40% per calendar year, and it was similar to that of non-CNS diseases and less evident after year 1998. In multivariable models, low CD4 cell count and high plasma viral load, but not HAART or calendar year, were significantly associated with risk to develop CNS disease, indicating that the effect of HAART was likely mediated by both improved immunological conditions and inhibition of viral replication. In contrast, use of nucleoside reverse transcriptase inhibitors, irrespective of use of protease inhibitors or non-nucleoside reverse transcriptase inhibitors, appeared to protect specifically against acquired immunodeficiency disease syndrome dementia complex, suggesting that, in this condition, therapy might have a direct, additive effect in the CNS.

show abstract

Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study

Cited by 36 publications

References 34 publications

Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database

Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

Changing incidence of central nervous system diseases in the EuroSIDA cohort

Contact Info

Product

Resources

About